These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 31910343)
21. LncRNA HOXC-AS3 increases non-small cell lung cancer cell migration and invasion by sponging premature miR-96. Wan L; Cheng Z; Sun Q; Jiang K Expert Rev Respir Med; 2022 May; 16(5):587-593. PubMed ID: 35034519 [TBL] [Abstract][Full Text] [Related]
22. Novel insights for lncRNA MAGI2-AS3 in solid tumors. Xue C; Li G; Lu J; Luo J; Jia J Biomed Pharmacother; 2021 May; 137():111429. PubMed ID: 33761624 [TBL] [Abstract][Full Text] [Related]
23. Long non-coding RNA MAGI2-AS3 inhibits breast cancer cell migration and invasion via sponging microRNA-374a. Du S; Hu W; Zhao Y; Zhou H; Wen W; Xu M; Zhao P; Liu K Cancer Biomark; 2019; 24(3):269-277. PubMed ID: 30883342 [TBL] [Abstract][Full Text] [Related]
24. Identification and Verification of a Novel MAGI2-AS3/miRNA-374-5p/FOXO1 Network Associated with HBV-Related HCC. Wang C; Su K; Lin H; Cen B; Zheng S; Xu X Cells; 2022 Nov; 11(21):. PubMed ID: 36359865 [TBL] [Abstract][Full Text] [Related]
25. MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis. Chang H; Zhang X; Li B; Meng X Cancer Med; 2020 Sep; 9(17):6377-6386. PubMed ID: 32681706 [TBL] [Abstract][Full Text] [Related]
26. Roles of lncRNA MAGI2-AS3 in human cancers. Kai-Xin L; Cheng C; Rui L; Zheng-Wei S; Wen-Wen T; Peng X Biomed Pharmacother; 2021 Sep; 141():111812. PubMed ID: 34126355 [TBL] [Abstract][Full Text] [Related]
27. LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression by targeting the miR-629-5p/TXNIP axis. Gong J; Ma L; Peng C; Liu J Ann Transl Med; 2021 Dec; 9(24):1793. PubMed ID: 35071487 [TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA MAGI2-AS3 inhibits bladder cancer progression through MAGI2/PTEN/epithelial-mesenchymal transition (EMT) axis. Shen D; Xu J; Cao X; Cao X; Tan H; Deng H Cancer Biomark; 2021; 30(2):155-165. PubMed ID: 33104021 [TBL] [Abstract][Full Text] [Related]
29. Hypermethylation-Mediated lncRNA MAGI2-AS3 Downregulation Facilitates Malignant Progression of Laryngeal Squamous Cell Carcinoma via Interacting With SPT6. Wang J; Yang C; Cao H; Yang J; Meng W; Yu M; Yu L; Wang B Cell Transplant; 2023; 32():9636897231154574. PubMed ID: 36852700 [TBL] [Abstract][Full Text] [Related]
30. Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells. Chen Z; Zhou J; Liu Y; Ni H; Zhou B Drug Dev Res; 2023 Nov; 84(7):1482-1495. PubMed ID: 37551766 [TBL] [Abstract][Full Text] [Related]
31. LncRNA MAGI2-AS3 promotes fracture healing through downregulation of miR-223-3p. Dong Z; Hu B; Wang S; Wang M; Sun S; Liu X; Li D; Wu D J Orthop Surg Res; 2024 Jun; 19(1):370. PubMed ID: 38907263 [TBL] [Abstract][Full Text] [Related]
32. LncRNA MAGI2-AS3 is downregulated in the distant recurrence of hepatocellular carcinoma after surgical resection and affects migration and invasion via ROCK2. Fang G; Wang J; Sun X; Xu R; Zhao X; Shao L; Sun C; Wang Y Ann Hepatol; 2020; 19(5):535-540. PubMed ID: 32546442 [TBL] [Abstract][Full Text] [Related]
33. LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia. Chen L; Fan X; Zhu J; Chen X; Liu Y; Zhou H RNA Biol; 2020 Jun; 17(6):784-793. PubMed ID: 32174258 [TBL] [Abstract][Full Text] [Related]
34. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling. Tang Y; Xiao G; Chen Y; Deng Y Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897 [TBL] [Abstract][Full Text] [Related]
35. LncRNA MAGI2-AS3 Affects Cell Invasion and Migration of Cervical Squamous Cell Carcinoma (CSCC) via Sponging miRNA-233/EPB41L3 Axis. Hou A; Zhang Y; Fan Y; Zheng Y; Zhou X; Liu H Cancer Manag Res; 2020; 12():4209-4216. PubMed ID: 32581592 [TBL] [Abstract][Full Text] [Related]
36. LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor HEY1 in clear cell renal cell carcinoma. Wang G; Li H; Hou Y Cancer Gene Ther; 2022 May; 29(5):585-596. PubMed ID: 34002044 [TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA LINC00243 promotes proliferation and glycolysis in non-small cell lung cancer cells by positively regulating PDK4 through sponging miR-507. Feng X; Yang S Mol Cell Biochem; 2020 Jan; 463(1-2):127-136. PubMed ID: 31595421 [TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA LINC00641 suppresses non-small-cell lung cancer by sponging miR-424-5p to upregulate PLSCR4. Li Y; Zhao L; Zhao P; Liu Z Cancer Biomark; 2019; 26(1):79-91. PubMed ID: 31322545 [TBL] [Abstract][Full Text] [Related]
39. Long non-coding RNA (lncRNA) MAGI2-AS3 inhibits breast cancer cell growth by targeting the Fas/FasL signalling pathway. Yang Y; Yang H; Xu M; Zhang H; Sun M; Mu P; Dong T; Du S; Liu K Hum Cell; 2018 Jul; 31(3):232-241. PubMed ID: 29679339 [TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNA FENDRR inhibits NSCLC cell growth and aggressiveness by sponging miR-761. Zhang MY; Zhang ZL; Cui HX; Wang RK; Fu L Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8324-8332. PubMed ID: 30556873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]